Pacira BioSciences
PCRX
191 hedge funds and large institutions have $3.48B invested in Pacira BioSciences in 2014 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 69 increasing their positions, 48 reducing their positions, and 21 closing their positions.
148% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 21
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
44% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 48
41% more capital invested
Capital invested by funds: $2.47B → $3.48B (+$1.02B)
19% more funds holding
Funds holding: 160 → 191 (+31)
9% less call options, than puts
Call options by funds: $11.2M | Put options by funds: $12.3M
Top Buyers
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$70.1M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$40.2M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$38.1M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$18.5M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$18.3M |
Top Sellers
| 1 |
VAM
Visium Asset Management
New York
|
-$45.1M |
| 2 |
DCM
Daruma Capital Management
New York
|
-$18.2M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$17.7M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$13.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$12.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
T
201
TradeWorx
Red Bank,
New Jersey
| – | -$801K | -11,441 | Closed |
|
|
PG
202
PEAK6 Group
Chicago,
Illinois
| – | -$737K | -10,534 | Closed |
|
|
SEC
203
Seven Eight Capital
New York
| – | -$707K | -10,100 | Closed |
|
|
ARC
204
Absolute Return Capital
Boston,
Massachusetts
| – | -$694K | -9,912 | Closed |
|
|
HLA
205
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$408K | -5,831 | Closed |
|
206
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$417K | -5,400 | Closed |
|
|
SIM
207
SSI Investment Management
Los Angeles,
California
| – | -$311K | -4,433 | Closed |
|
|
PA
208
Perceptive Advisors
New York
| – | -$139K | -2,000 | Closed |
|
|
BJ
209
BlackRock Japan
Tokyo,
Japan
| – | -$138K | -1,978 | Closed |
|
|
BRWM
210
B. Riley Wealth Management
Memphis,
Tennessee
| – | -$133K | -1,901 | Closed |
|
|
CCS
211
Crosspoint Capital Strategies
Orinda,
California
| – | -$11K | -151 | Closed |
|
|
NES
212
New England Securities
New York
| – | -$4K | -60 | Closed |
|
PCRX Hedge Fund Activity: Q2 2014 in Review
191 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2014, worth a combined $3.48B — up 41% from $2.47B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new PCRX positions and 21 closed out — a net gain of 31 holders — while 69 added to existing stakes and 48 trimmed.
The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $70.1M. The largest seller was Visium Asset Management, cutting an estimated $45.1M.
- 191 institutional investors held Pacira BioSciences (PCRX) as of Q2 2014, up from 160 in Q1 2014.
- Funds reported $3.48B of Pacira BioSciences stock for Q2 2014, up 41% quarter-over-quarter.
- 52 funds opened new Pacira BioSciences positions in Q2 2014 and 21 closed out, a net change of +31 holders.
- The largest Pacira BioSciences buyer in Q2 2014 was Janus Henderson Investors US, an estimated $70.1M added.
- The largest Pacira BioSciences seller in Q2 2014 was Visium Asset Management, an estimated $45.1M sold.
Based on aggregated 13F filings for Q2 2014.